查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1661108

2025 年至 2033 年生物製药市场报告，按适应症（自体免疫疾病、肿瘤学、代谢紊乱等）、类别（重组蛋白、单株抗体、纯化蛋白）和地区划分

Biopharmaceutical Market Report by Indication (Autoimmune Diseases, Oncology, Metabolic Disorders, and Others), Class (Recombinant Proteins, Monoclonal Antibodies, Purified Proteins), and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 145 Pages | 商品交期: 2-3个工作天内

价格

2024IMARC Group全球生物製药市场规模达到 3,262 亿美元。慢性病发病率不断上升、生物製药的重大进步、政府支持和医疗支出的增加、个人化医疗和标靶治疗、生物相似药的扩张以及人工智慧和机器学习的利用率不断提高等因素推动了市场的发展。

生物製药，也称为生物製剂，是一类源自生物来源的药物。它们是利用细菌、酵母或哺乳动物细胞等生物体透过生物技术过程生产的。与化学合成的传统小分子药物不同，生物製药是大型复杂分子，与体内的生物标靶表现出高度特异性的相互作用。与传统药物相比，它们具有多种优势。它们的作用往往具有高度特异性，通常针对特定的受体或分子，从而提高疗效并减少副作用。此外，生物製药还有潜力治疗以前难以用传统药物治疗的疾病。

由于个人化医疗需求不断增加，市场正在经历显着成长。此外，生物製药在治疗癌症、糖尿病、牛皮癣和类风湿性关节炎方面的应用越来越广泛，这也是另一个主要的成长诱导因素。此外，大众对生物製药的有效性和可用性的认识不断提高，这是另一个重要的成长因素。此外，对罕见疾病和孤儿药的日益关注正在推动市场的成长。这些罕见疾病通常以患者人数少为特征，存在着巨大的未满足的医疗需求。除此之外，世界各国政府和监管机构都推出了激励措施并简化了监管流程，以鼓励开发这些疾病的治疗方法。此外，生物製药公司正在投资研发针对罕见疾病的孤儿药，从而解决关键医疗需求并为市场扩张创造机会。

生物製药市场趋势/驱动因素：

个人化医疗需求不断成长

个人化医疗已导致生物製药市场向标靶治疗和精准医疗方法的转变。生物製药公司越来越注重开发针对特定基因突变、生物标记或与疾病相关的分子路径的治疗方法。此外，个人化医疗推动了药物基因组学的进步，该学科是研究个人基因组成如何影响其对药物的反应。了解影响药物代谢、功效和安全性的基因变异可以识别可能有不良反应风险的患者或更有可能对特定治疗产生良好反应的患者。这些知识使生物製药公司能够针对个别患者制定针对性的治疗方法和给药方案，从而提高治疗效果并降低不良事件的风险。

慢性病和生活方式相关疾病的盛行率不断上升

慢性疾病，包括心血管疾病、糖尿病、癌症、呼吸系统疾病和自体免疫疾病，已成为全球主要的健康挑战。这些疾病通常具有复杂的潜在机制，需要有针对性的个人化治疗方法。单株抗体、重组蛋白和基因疗法等生物製药可提供精准的标靶和客製化的治疗方案。这些疗法可以针对与慢性疾病相关的特定分子路径、受体或细胞，从而提高疗效并减少副作用。此外，慢性病和生活方式相关疾病的负担越来越重，人们的关注点从缓解症状转移到改善疾病和预防，这也推动了市场的成长。

生物技术的各种进步

生物技术大大加速了药物发现和开发的进程。高通量筛选、组合化学和计算建模等先进技术能够在更短的时间内识别和测试大量候选药物。这提高了药物研发的效率和速度，使生物製药公司能够更快地将新疗法推向市场。此外，分析个别基因组成、识别疾病标记和了解分子路径的能力使得针对特定患者群体的标靶治疗方法的开发成为可能。基因组学、下一代定序和基因编辑技术等生物技术工具彻底改变了人们对疾病机制的理解，并推动了针对特定基因变异和分子标靶的治疗方法的开发，从而推动了市场的发展。

目录

第 1 章：前言

第 2 章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

第五章：全球生物製药市场

  • 市场表现及预测
    • 当前表现（2019-2024）
    • 市场预测（2025-2033）
  • COVID-19 的影响
  • 市场：按区域
    • 当前表现（2019-2024）
    • 市场预测（2025-2033）
  • 市场：按适应症
    • 自体免疫疾病
    • 肿瘤学
    • 代谢紊乱
    • 其他的
  • 市场：按类别
    • 重组蛋白
      • 当前表现（2019-2024）
      • 市场预测（2025-2033）
    • 单株抗体
      • 当前表现（2019-2024）
      • 市场预测（2025-2033）
    • 纯化蛋白质
      • 当前表现（2019-2024）
      • 市场预测（2025-2033）
  • 竞争格局
    • 顶尖生物製药公司
    • 顶级生物製药药物
  • 价值链分析
  • 波特五力分析
    • 概述
    • 买家的议价能力
    • 供应商的议价能力
    • 竞争程度
    • 新进入者的威胁
    • 替代品的威胁

第 6 章：北美

  • 美国
    • 市场表现（2019-2024）
    • 市场：按类别
      • 重组蛋白
      • 单株抗体
      • 纯化蛋白质
    • 顶级玩家
    • 市场预测（2025-2033）
  • 加拿大
    • 市场表现（2019-2024）
    • 市场：按类别
      • 重组蛋白
      • 单株抗体
      • 纯化蛋白质
    • 顶级玩家
    • 市场预测（2025-2033）

第 7 章：拉丁美洲

  • 墨西哥
    • 市场表现（2019-2024）
    • 市场：按类别
      • 重组蛋白
      • 单株抗体
      • 纯化蛋白质
    • 顶级玩家
    • 市场预测（2025-2033）
  • 巴西
    • 市场表现（2019-2024）
    • 市场：按类别
      • 重组蛋白
      • 单株抗体
      • 纯化蛋白质
    • 顶级玩家
    • 市场预测（2025-2033）
  • 阿根廷
    • 市场表现（2019-2024）
    • 市场：按类别
      • 重组蛋白
      • 单株抗体
      • 纯化蛋白质
    • 顶级玩家
    • 市场预测（2025-2033）

第 8 章：欧洲

  • 德国
    • 市场表现（2019-2024）
    • 市场：按类别
      • 重组蛋白
      • 单株抗体
      • 纯化蛋白质
    • 顶级玩家
    • 市场预测（2025-2033）
  • 法国
    • 市场表现（2019-2024）
    • 市场：按类别
      • 重组蛋白
      • 单株抗体
      • 纯化蛋白质
    • 顶级玩家
    • 市场预测（2025-2033）
  • 义大利
    • 市场表现（2019-2024）
    • 市场：按类别
      • 重组蛋白
      • 单株抗体
      • 纯化蛋白质
    • 顶级玩家
    • 市场预测（2025-2033）
  • 西班牙
    • 市场表现（2019-2024）
    • 市场：按类别
      • 重组蛋白
      • 单株抗体
      • 纯化蛋白质
    • 顶级玩家
    • 市场预测（2025-2033）
  • 英国
    • 市场表现（2019-2024）
    • 市场：按类别
      • 重组蛋白
      • 单株抗体
      • 纯化蛋白质
    • 顶级玩家
    • 市场预测（2025-2033）
  • 俄罗斯
    • 市场表现（2019-2024）
    • 市场：按类别
      • 重组蛋白
      • 单株抗体
      • 纯化蛋白质
    • 顶级玩家
    • 市场预测（2025-2033）
  • 土耳其
    • 市场表现（2019-2024）
    • 市场：按类别
      • 重组蛋白
      • 单株抗体
      • 纯化蛋白质
    • 顶级玩家
    • 市场预测（2025-2033）

第 9 章：亚太地区

  • 日本
    • 市场表现（2019-2024）
    • 市场：按类别
      • 重组蛋白
      • 单株抗体
      • 纯化蛋白质
    • 顶级玩家
    • 市场预测（2025-2033）
  • 中国
    • 市场表现（2019-2024）
    • 市场：按类别
      • 重组蛋白
      • 单株抗体
      • 纯化蛋白质
    • 顶级玩家
    • 市场预测（2025-2033）
  • 澳洲
    • 市场表现（2019-2024）
    • 市场：按类别
      • 重组蛋白
      • 单株抗体
      • 纯化蛋白质
    • 顶级玩家
    • 市场预测（2025-2033）
  • 韩国
    • 市场表现（2019-2024）
      • 重组蛋白
      • 单株抗体
      • 纯化蛋白质
    • 顶级玩家
    • 市场预测（2025-2033）
  • 印度
    • 市场表现（2019-2024）
    • 市场：按类别
      • 重组蛋白
      • 单株抗体
      • 纯化蛋白质
    • 顶级玩家
    • 市场预测（2025-2033）
  • 印尼
    • 市场表现（2019-2024）
    • 市场：按类别
      • 重组蛋白
      • 单株抗体
      • 纯化蛋白质
    • 顶级玩家
    • 市场预测（2025-2033）

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AbbVie Inc.
    • Amgen Inc
    • Biogen Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Sanofi SA
Product Code: SR112025A722

The global biopharmaceutical market size reached USD 326.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 664.8 Billion by 2033, exhibiting a growth rate (CAGR) of 8.2% during 2025-2033. The market has been propelled by the increasing prevalence of chronic illnesses, significant advancements in biopharmaceutical, rising government support and healthcare expenditure, personalized medicine and targeted therapies, expansion of biosimilars, and increasing utilization of artificial intelligence and machine learning.

Biopharmaceuticals, also known as biologics, are a class of pharmaceutical drugs derived from biological sources. They are produced using living organisms, such as bacteria, yeast, or mammalian cells, through biotechnological processes. Unlike traditional small-molecule drugs, which are chemically synthesized, biopharmaceuticals are large, complex molecules that exhibit highly specific interactions with biological targets in the body. They offer several advantages over traditional pharmaceuticals. They tend to be highly specific in their action, often targeting specific receptors or molecules, resulting in increased efficacy and reduced side effects. Additionally, biopharmaceuticals have the potential to treat diseases that were previously challenging to address using conventional drugs.

The market is experiencing significant growth due to the escalating demand for personalized medicine. In addition, the increasing utilization of biopharmaceuticals to treat cancer, diabetes, psoriasis, and rheumatoid arthritis represents another major growth-inducing factor. Besides, the growing awareness among the masses regarding the effectiveness and availability of biopharmaceuticals represents another major growth-inducing factor. Moreover, the rising focus on rare diseases and orphan drugs is driving the growth of the market. These rare diseases, often characterized by small patient populations, present significant unmet medical needs. Other than this, governments and regulatory agencies worldwide have introduced incentives and streamlined regulatory processes to encourage the development of therapies for these conditions. Moreover, biopharmaceutical companies are investing in R&D to develop orphan drugs, which target rare diseases, thereby addressing critical medical needs and creating opportunities for market expansion.

Biopharmaceutical Market Trends/Drivers:

The escalating demand for personalized medicine

Personalized medicine has led to a shift toward targeted therapies and precision medicine approaches in the biopharmaceutical market. Biopharmaceutical companies are increasingly focusing on the development of therapies that target specific genetic mutations, biomarkers, or molecular pathways associated with diseases. Moreover, personalized medicine has led to advancements in pharmacogenomics, which is the study of how an individual's genetic makeup influences their response to drugs. Understanding the genetic variations that impact drug metabolism, efficacy, and safety allows for the identification of patients who may be at risk of adverse reactions or those who are more likely to respond favorably to a specific treatment. This knowledge enables biopharmaceutical companies to develop targeted therapies and dosage regimens tailored to individual patients, enhancing treatment effectiveness and reducing the risk of adverse events.

The growing prevalence of chronic and lifestyle-related diseases

Chronic diseases, including cardiovascular disorders, diabetes, cancer, respiratory diseases, and autoimmune conditions, have become major global health challenges. These diseases often have complex underlying mechanisms, requiring targeted and personalized treatment approaches. Biopharmaceuticals, such as monoclonal antibodies, recombinant proteins, and gene therapies, offer precise targeting and tailored treatment options. These therapies can target specific molecular pathways, receptors, or cells associated with chronic diseases, resulting in enhanced efficacy and reduced side effects. Moreover, the increasing burden of chronic and lifestyle-related diseases has shifted the focus from symptomatic relief to disease modification and prevention, which is also propelling the market growth.

Various advancements in biotechnology

Biotechnology has greatly accelerated the drug discovery and development process. Advanced techniques, such as high-throughput screening, combinatorial chemistry, and computational modeling, enable the identification and testing of a large number of drug candidates in a shorter time frame. This has led to an increase in the efficiency and speed of drug discovery, allowing biopharmaceutical companies to bring new therapies to market more rapidly. Besides, the ability to analyze an individual's genetic makeup, identify disease markers, and understand molecular pathways has enabled the development of targeted therapies tailored to specific patient populations. Biotechnology tools, such as genomics, next-generation sequencing, and gene editing techniques, have revolutionized the understanding of disease mechanisms and enabled the development of therapies that address specific genetic variations and molecular targets, thus propelling the market.

Biopharmaceutical Industry Segmentation:

Breakup by Indication:

  • Autoimmune Diseases
  • Oncology
  • Metabolic Disorders
  • Others

Autoimmune diseases represent the leading segment

Autoimmune diseases are often chronic and complex conditions that require long-term management and treatment. These diseases can affect multiple organs and systems in the body, leading to a wide range of symptoms and complications. Biopharmaceutical therapies have shown promising results in managing and controlling autoimmune diseases, providing relief from symptoms, slowing disease progression, and improving quality of life for patients. Therapies, including monoclonal antibodies and other biologics, have emerged as a vital treatment option for autoimmune diseases. They target specific molecules, cells, or pathways involved in the autoimmune response, providing more precise and effective therapeutic interventions.

Breakup by Class:

  • Recombinant Proteins
  • Monoclonal Antibodies
  • Purified Proteins

Monoclonal antibodies exhibit a clear dominance in the market

Monoclonal antibodies are highly specific in targeting disease-specific antigens or cells. They are designed to bind to a specific target with precision, minimizing off-target effects and reducing the risk of adverse reactions. This specificity contributes to their efficacy in treating various diseases, including autoimmune disorders, cancer, inflammatory conditions, and infectious diseases. They also have a wide range of therapeutic applications across different disease areas. They can be used as therapeutic agents on their own or in combination with other treatments. Monoclonal antibodies have been successful in neutralizing pathogens, blocking cell receptors, modulating immune responses, and delivering therapeutic payloads, making them versatile tools for disease management.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Turkey
  • Asia Pacific
  • Japan
  • China
  • Australia
  • South Korea
  • India
  • Indonesia

North America accounts for the majority of market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Latin America (Mexico, Brazil, and Argentina); Europe (Germany, France, Italy, Spain, the United Kingdom, Russia, and Turkey); and Asia Pacific (Japan, China, Australia, South Korea, India, and Indonesia). According to the report, North America was the largest market for biopharmaceuticals.

North America, particularly the United States, boasts a highly developed healthcare infrastructure, including robust research and development capabilities, advanced clinical facilities, and a strong regulatory framework. The region is home to renowned academic institutions, pharmaceutical companies, and research organizations that drive innovation in the biopharmaceutical industry. The presence of these institutions and infrastructure facilitates the development, manufacturing, and commercialization of biopharmaceutical products. The region has a well-established ecosystem that supports biopharmaceutical innovation, including government funding initiatives, research grants, venture capital investments, and collaborations between academia, industry, and research institutes.

Competitive Landscape:

The competitive landscape of the biopharmaceutical market is highly dynamic and competitive, with numerous global and regional players vying for market share. Nowadays, leading biopharmaceutical companies are heavily investing in R&D to discover and develop innovative therapies. They are conducting preclinical and clinical trials, and advance promising candidates through the regulatory approval process. These investments aim to expand their product pipelines, address unmet medical needs, and stay ahead of competitors in terms of therapeutic advancements. They are also forming strategic partnerships and collaborations with academic institutions, research organizations, and other industry players. These alliances enable them to access new technologies, scientific expertise, and complementary resources.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • AbbVie Inc.
  • Amgen Inc
  • Biogen Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi S.A

Recent Developments:

Pfizer and BioNTech developed and distributed their mRNA-based COVID-19 vaccine, Comirnaty (BNT162b2). The vaccine received emergency use authorizations and has been widely deployed globally, playing a crucial role in combating the COVID-19 pandemic.

Amgen Inc. recently received FDA approval for Lumakras (sotorasib), a targeted therapy for non-small cell lung cancer (NSCLC) with specific genetic mutations.

AbbVie Inc. has made significant advancements in immunology, particularly with its flagship product, Humira (adalimumab). Humira is one of the world's best-selling biologic drugs used to treat autoimmune conditions, including rheumatoid arthritis, psoriasis, and Crohn's disease.

Key Questions Answered in This Report

  • 1.What was the size of the global biopharmaceutical market in 2024?
  • 2.What is the expected growth rate of the global biopharmaceutical market during 2025-2033?
  • 3.What are the key factors driving the global biopharmaceutical market?
  • 4.What has been the impact of COVID-19 on the global biopharmaceutical market?
  • 5.What is the breakup of the global biopharmaceutical market based on the indication?
  • 6.What is the breakup of the global biopharmaceutical market based on the class?
  • 7.What are the key regions in the global biopharmaceutical market?
  • 8.Who are the key players/companies in the global biopharmaceutical market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

5 Global Biopharmaceutical Market

  • 5.1 Market Performance and Forecast
    • 5.1.1 Current Performance (2019-2024)
    • 5.1.2 Market Forecast (2025-2033)
  • 5.2 Impact of COVID-19
  • 5.3 Market by Region
    • 5.3.1 Current Performance (2019-2024)
    • 5.3.2 Market Forecast (2025-2033)
  • 5.4 Market by Indication
    • 5.4.1 Autoimmune Diseases
    • 5.4.2 Oncology
    • 5.4.3 Metabolic Disorders
    • 5.4.4 Others
  • 5.5 Market by Class
    • 5.5.1 Recombinant Proteins
      • 5.5.1.1 Current Performance (2019-2024)
      • 5.5.1.2 Market Forecast (2025-2033)
    • 5.5.2 Monoclonal Antibodies
      • 5.5.2.1 Current Performance (2019-2024)
      • 5.5.2.2 Market Forecast (2025-2033)
    • 5.5.3 Purified Proteins
      • 5.5.3.1 Current Performance (2019-2024)
      • 5.5.3.2 Market Forecast (2025-2033)
  • 5.6 Competitive Landscape
    • 5.6.1 Top Biopharmaceutical Players
    • 5.6.2 Top Biopharmaceutical Drugs
  • 5.7 Value Chain Analysis
  • 5.8 Porter's Five Forces Analysis
    • 5.8.1 Overview
    • 5.8.2 Bargaining Power of Buyers
    • 5.8.3 Bargaining Power of Suppliers
    • 5.8.4 Degree of Rivalry
    • 5.8.5 Threat of New Entrants
    • 5.8.6 Threat of Substitutes

6 North America

  • 6.1 United States
    • 6.1.1 Market Performance (2019-2024)
    • 6.1.2 Market by Class
      • 6.1.2.1 Recombinant Proteins
      • 6.1.2.2 Monoclonal Antibodies
      • 6.1.2.3 Purified Proteins
    • 6.1.3 Top Players
    • 6.1.4 Market Forecast (2025-2033)
  • 6.2 Canada
    • 6.2.1 Market Performance (2019-2024)
    • 6.2.2 Market by Class
      • 6.2.2.1 Recombinant Proteins
      • 6.2.2.2 Monoclonal Antibodies
      • 6.2.2.3 Purified Proteins
    • 6.2.3 Top Players
    • 6.2.4 Market Forecast (2025-2033)

7 Latin America

  • 7.1 Mexico
    • 7.1.1 Market Performance (2019-2024)
    • 7.1.2 Market by Class
      • 7.1.2.1 Recombinant Proteins
      • 7.1.2.2 Monoclonal Antibodies
      • 7.1.2.3 Purified Proteins
    • 7.1.3 Top Players
    • 7.1.4 Market Forecast (2025-2033)
  • 7.2 Brazil
    • 7.2.1 Market Performance (2019-2024)
    • 7.2.2 Market by Class
      • 7.2.2.1 Recombinant Proteins
      • 7.2.2.2 Monoclonal Antibodies
      • 7.2.2.3 Purified Proteins
    • 7.2.3 Top Players
    • 7.2.4 Market Forecast (2025-2033)
  • 7.3 Argentina
    • 7.3.1 Market Performance (2019-2024)
    • 7.3.2 Market by Class
      • 7.3.2.1 Recombinant Proteins
      • 7.3.2.2 Monoclonal Antibodies
      • 7.3.2.3 Purified Proteins
    • 7.3.3 Top Players
    • 7.3.4 Market Forecast (2025-2033)

8 Europe

  • 8.1 Germany
    • 8.1.1 Market Performance (2019-2024)
    • 8.1.2 Market by Class
      • 8.1.2.1 Recombinant Proteins
      • 8.1.2.2 Monoclonal Antibodies
      • 8.1.2.3 Purified Proteins
    • 8.1.3 Top Players
    • 8.1.4 Market Forecast (2025-2033)
  • 8.2 France
    • 8.2.1 Market Performance (2019-2024)
    • 8.2.2 Market by Class
      • 8.2.2.1 Recombinant Proteins
      • 8.2.2.2 Monoclonal Antibodies
      • 8.2.2.3 Purified Proteins
    • 8.2.3 Top Players
    • 8.2.4 Market Forecast (2025-2033)
  • 8.3 Italy
    • 8.3.1 Market Performance (2019-2024)
    • 8.3.2 Market by Class
      • 8.3.2.1 Recombinant Proteins
      • 8.3.2.2 Monoclonal Antibodies
      • 8.3.2.3 Purified Proteins
    • 8.3.3 Top Players
    • 8.3.4 Market Forecast (2025-2033)
  • 8.4 Spain
    • 8.4.1 Market Performance (2019-2024)
    • 8.4.2 Market by Class
      • 8.4.2.1 Recombinant Proteins
      • 8.4.2.2 Monoclonal Antibodies
      • 8.4.2.3 Purified Proteins
    • 8.4.3 Top Players
    • 8.4.4 Market Forecast (2025-2033)
  • 8.5 United Kingdom
    • 8.5.1 Market Performance (2019-2024)
    • 8.5.2 Market by Class
      • 8.5.2.1 Recombinant Proteins
      • 8.5.2.2 Monoclonal Antibodies
      • 8.5.2.3 Purified Proteins
    • 8.5.3 Top Players
    • 8.5.4 Market Forecast (2025-2033)
  • 8.6 Russia
    • 8.6.1 Market Performance (2019-2024)
    • 8.6.2 Market by Class
      • 8.6.2.1 Recombinant Proteins
      • 8.6.2.2 Monoclonal Antibodies
      • 8.6.2.3 Purified Proteins
    • 8.6.3 Top Players
    • 8.6.4 Market Forecast (2025-2033)
  • 8.7 Turkey
    • 8.7.1 Market Performance (2019-2024)
    • 8.7.2 Market by Class
      • 8.7.2.1 Recombinant Proteins
      • 8.7.2.2 Monoclonal Antibodies
      • 8.7.2.3 Purified Proteins
    • 8.7.3 Top Players
    • 8.7.4 Market Forecast (2025-2033)

9 Asia Pacific

  • 9.1 Japan
    • 9.1.1 Market Performance (2019-2024)
    • 9.1.2 Market by Class
      • 9.1.2.1 Recombinant Proteins
      • 9.1.2.2 Monoclonal Antibodies
      • 9.1.2.3 Purified Proteins
    • 9.1.3 Top Players
    • 9.1.4 Market Forecast (2025-2033)
  • 9.2 China
    • 9.2.1 Market Performance (2019-2024)
    • 9.2.2 Market by Class
      • 9.2.2.1 Recombinant Proteins
      • 9.2.2.2 Monoclonal Antibodies
      • 9.2.2.3 Purified Proteins
    • 9.2.3 Top Players
    • 9.2.4 Market Forecast (2025-2033)
  • 9.3 Australia
    • 9.3.1 Market Performance (2019-2024)
    • 9.3.2 Market by Class
      • 9.3.2.1 Recombinant Proteins
      • 9.3.2.2 Monoclonal Antibodies
      • 9.3.2.3 Purified Proteins
    • 9.3.3 Top Players
    • 9.3.4 Market Forecast (2025-2033)
  • 9.4 South Korea
    • 9.4.1 Market Performance (2019-2024)
      • 9.4.1.1 Recombinant Proteins
      • 9.4.1.2 Monoclonal Antibodies
      • 9.4.1.3 Purified Proteins
    • 9.4.2 Top Players
    • 9.4.3 Market Forecast (2025-2033)
  • 9.5 India
    • 9.5.1 Market Performance (2019-2024)
    • 9.5.2 Market by Class
      • 9.5.2.1 Recombinant Proteins
      • 9.5.2.2 Monoclonal Antibodies
      • 9.5.2.3 Purified Proteins
    • 9.5.3 Top Players
    • 9.5.4 Market Forecast (2025-2033)
  • 9.6 Indonesia
    • 9.6.1 Market Performance (2019-2024)
    • 9.6.2 Market by Class
      • 9.6.2.1 Recombinant Proteins
      • 9.6.2.2 Monoclonal Antibodies
      • 9.6.2.3 Purified Proteins
    • 9.6.3 Top Players
    • 9.6.4 Market Forecast (2025-2033)

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Competitive Landscape

  • 11.1 Market Structure
  • 11.2 Key Players
  • 11.3 Profiles of Key Players
    • 11.3.1 AbbVie Inc.
    • 11.3.2 Amgen Inc
    • 11.3.3 Biogen Inc.
    • 11.3.4 Eli Lilly and Company
    • 11.3.5 F. Hoffmann-La Roche AG
    • 11.3.6 Johnson & Johnson
    • 11.3.7 Merck & Co. Inc.
    • 11.3.8 Novo Nordisk A/S
    • 11.3.9 Pfizer Inc.
    • 11.3.10 Sanofi S.A

List of Figures

  • Figure 1: Global: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 2: Complexity of Biopharmaceuticals
  • Figure 3: Sources of Biopharmaceuticals
  • Figure 4: Global: Biopharmaceutical Market: Value Trends (in Billion USD), 2019-2024
  • Figure 5: Global: Biopharmaceutical Market Forecast: Value Trends (in Billion USD), 2025-2033
  • Figure 6: Global: Biopharmaceutical Market: Sales Share by Country (in %), 2024
  • Figure 7: Global: Biopharmaceutical Market Forecast: Sales Share by Country (in %), 2033
  • Figure 8: Global: Biopharmaceutical Market: Sales Share by Indication (in %), 2024
  • Figure 9: Global: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 10: Global: Biopharmaceutical Market Forecast: Sales by Class (in Million USD), 2025-2033
  • Figure 11: Global: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 12: Global: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 13: Global: Recombinant Proteins Market Forecast (in Million USD), 2025-2033
  • Figure 14: Global: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 15: Global: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 16: Global: Monoclonal Antibodies Market Forecast (in Million USD), 2025-2033
  • Figure 17: Global: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 18: Global: Purified Proteins Market: Sales Share by Class (in %), 2024
  • Figure 19: Global: Purified Proteins Market Forecast (in Million USD), 2025-2033
  • Figure 20: Global: Biopharmaceutical Market: Sales Share of Top Biopharmaceuticals (in %)
  • Figure 21: Global: Biopharmaceutical Industry: Value Chain Analysis
  • Figure 22: Global: Biopharmaceutical Industry: Porter's Five Forces Analysis
  • Figure 23: United States: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 24: United States: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 25: United States: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 26: United States: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 27: United States: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 28: United States: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 29: United States: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 30: United States: Purified Proteins Market: Sales Share by Class (in %), 2024
  • Figure 31: United States: Biopharmaceutical Market: Sales Share of Top Players (in %), 2024
  • Figure 32: United States: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 33: United States: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 34: Canada: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 35: Canada: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 36: Canada: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 37: Canada: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 38: Canada: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 39: Canada: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 40: Canada: Biopharmaceutical Market: Sales Share of Top Players (in %), 2024
  • Figure 41: Canada: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 42: Canada: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 43: Mexico: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 44: Mexico: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 45: Mexico: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 46: Mexico: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 47: Mexico: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 48: Mexico: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 49: Mexico: Purified Proteins Market (in '000 USD), 2019-2024
  • Figure 50: Mexico: Biopharmaceutical Market: Sales Share of Top Players (in %), 2024
  • Figure 51: Mexico: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 52: Mexico: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 53: Brazil: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 54: Brazil: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 55: Brazil: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 56: Brazil: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 57: Brazil: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 58: Brazil: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 59: Brazil: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 60: Brazil: Biopharmaceutical Market: Sales Share of Top Players (in %), 2024
  • Figure 61: Brazil: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 62: Brazil: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 63: Argentina: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 64: Argentina: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 65: Argentina: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 66: Argentina: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 67: Argentina: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 68: Argentina: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 69: Argentina: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 70: Argentina: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 71: Argentina: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 72: Argentina: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 73: Germany: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 74: Germany: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 75: Germany: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 76: Germany: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 77: Germany: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 78: Germany: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 79: Germany: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 80: Germany: Purified Proteins Market: Sales Share by Class (in %), 2024
  • Figure 81: Germany: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 82: Germany: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 83: Germany: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 84: France: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 85: France: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 86: France: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 87: France: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 88: France: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 89: France: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 90: France: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 91: France: Biopharmaceutical Market: Sales Share of Top Players (in %), 2024
  • Figure 92: France: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 93: France: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 94: Italy: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 95: Italy: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 96: Italy: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 97: Italy: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 98: Italy: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 99: Italy: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 100: Italy: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 101: Italy: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 102: Italy: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 103: Italy: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 104: Spain: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 105: Spain: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 106: Spain: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 107: Spain: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 108: Spain: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 109: Spain: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 110: Spain: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 111: Spain: Purified Proteins Market: Sales Share by Class (in %), 2024
  • Figure 112: Spain: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 113: Spain: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 114: Spain: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 115: UK: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 116: UK: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 117: UK: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 118: UK: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 119: UK: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 120: UK: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 121: UK: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 122: UK: Purified Proteins Market: Sales Share by Class (in %), 2024
  • Figure 123: UK: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 124: UK: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 125: UK: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 126: Russia: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 127: Russia: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 128: Russia: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 129: Russia: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 130: Russia: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 131: Russia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 132: Russia: Purified Proteins Market: (in Million USD), 2019-2024
  • Figure 133: Russia: Purified Proteins Market: Sales Share by Class (in %), 2024
  • Figure 134: Russia: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 135: Russia: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 136: Russia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 137: Turkey: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 138: Turkey: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 139: Turkey: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 140: Turkey: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 141: Turkey: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 142: Turkey: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 143: Turkey: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 144: Turkey: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 145: Turkey: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 146: Japan: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 147: Japan: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 148: Japan: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 149: Japan: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 150: Japan: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 151: Japan: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 152: Japan: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 153: Japan: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 154: Japan: Biopharmaceutical Market Forecast: Value trend (in Million USD), 2025-2033
  • Figure 155: Japan: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 156: China: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 157: China: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 158: China: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 159: China: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 160: China: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 161: China: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 162: China: Purified Proteins Market: (in Million USD), 2019-2024
  • Figure 163: China: Purified Proteins Market: Sales Share by Class (in %), 2024
  • Figure 164: China: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 165: China: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 166: China: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 167: Australia: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 168: Australia: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 169: Australia: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 170: Australia: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 171: Australia: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 172: Australia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 173: Australia: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 174: Australia: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 175: Australia: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 176: Australia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 177: South Korea: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 178: South Korea: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 179: South Korea: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 180: South Korea: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 181: South Korea: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 182: South Korea: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2024
  • Figure 183: South Korea: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 184: South Korea: Purified Proteins Market: Sales Share by Class (in %), 2024
  • Figure 185: South Korea: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 186: South Korea: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 187: South Korea: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 188: India: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 189: India: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 190: India: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 191: India: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 192: India: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 193: India: Purified Proteins Market (in Million USD), 2019-2024
  • Figure 194: India: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 195: India: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 196: India: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 197: Indonesia: Biopharmaceutical Market (in Million USD), 2019-2024
  • Figure 198: Indonesia: Biopharmaceutical Market: Sales by Class (in Million USD), 2019-2024
  • Figure 199: Indonesia: Recombinant Proteins Market (in Million USD), 2019-2024
  • Figure 200: Indonesia: Recombinant Proteins Market: Sales Share by Class (in %), 2024
  • Figure 201: Indonesia: Monoclonal Antibodies Market (in Million USD), 2019-2024
  • Figure 202: Indonesia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2024
  • Figure 203: Indonesia: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 204: Indonesia: Biopharmaceutical Market Forecast (in Million USD), 2025-2033
  • Figure 205: Indonesia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2033
  • Figure 206: Global: Share of Biopharmaceuticals & Small Molecule Drugs Among the Top Ten Selling Drugs (in %), 2001 & 2022
  • Figure 207: Using a Different Manufacturing Process Makes it Extremely Difficult for Biosimilars to be Equivalent to Originator Products
  • Figure 208: Marked Differences Between Biosimilar and Branded Biopharmaceuticals When a Different Production Process was Used
  • Figure 209: Transition Probabilities of Biopharmaceuticals & Small Molecule Drugs in Clinical Phases, (in %)
  • Figure 210: Comparison of the Average Annual Cost of Therapy Using Biopharmaceuticals and Small Molecule Drugs (in USD)
  • Figure 211: Emerging Biopharmaceutical Market Forecast (in Million USD), 2024 & 2033
  • Figure 212: Developed Biopharmaceutical Market Forecast (in Million USD), 2024 & 2033
  • Figure 213: Breakup of Biopharmaceuticals and Small Molecule Drugs Receiving FDA Approval (in Numbers), 2002-2022
  • Figure 214: A Comparison of the Costs Incurred While Developing Biopharmaceuticals and Small Molecule Drugs (in Million USD)
  • Figure 215: Comparison of the Research & Development Times for Biopharmaceuticals & Small Molecule Drugs (in Months)

List of Tables

  • Table 1: Global: Biopharmaceutical Market: Definition & Segmentation
  • Table 2: Global: Biopharmaceutical Market: SWOT Analysis
  • Table 3: Global: Biopharmaceutical Market Forecast: Sales by Region (in Million USD), 2024 & 2033
  • Table 4: Differences Between Small Molecule Drugs & Biopharmaceuticals
  • Table 5: Complexity of Manufacturing Process Involved with Biopharmaceuticals & Small Molecule Drugs
  • Table 6: Global: Biopharmaceutical Market: Sales by Country (in Million USD), 2019-2024
  • Table 7: Global: Biopharmaceutical Market Forecast: Sales by Country (in Million USD), 2025-2033
  • Table 8: Global: Biopharmaceutical Market: Sales by Indication (in Billion USD), 2024
  • Table 9: Mode of Administration of Popular Biotech Drugs